本文已被:浏览 38次 下载 51次
投稿时间:2023-08-11 网络发布日期:2024-08-20
投稿时间:2023-08-11 网络发布日期:2024-08-20
中文摘要: 目的 观察联合应用阿加曲班及纤溶酶对急性脑梗死(ACI)患者神经功能缺损程度、血中性粒细胞(NEUT)计数的影响及其安全性。方法 选取2018年10月至2022年1月大连医科大学附属第一医院收治的221例ACI患者,将其随机分为常规组(n=71)、纤溶酶组(n=42)、阿加曲班组(n=40)及联合组(n=68)。四组均给予常规治疗,常规组不加其他治疗。纤溶酶组加用纤溶酶注射液,治疗第1天用量100 IU,第2天开始300 IU,静脉滴注。阿加曲班组每天加用阿加曲班注射液10 mg/12h静脉泵入。联合组每天加用阿加曲班注射液及纤溶酶注射液(用法同前)。分析治疗前后神经功能缺损评分和血NEUT计数的变化及治疗期间不良反应情况。结果 治疗后,除常规组外其他三组美国国立卫生研究院神经功能缺损评分(NIHSS)均较治疗前下降(P<0.01),联合组NIHSS评分显著低于常规组、纤溶酶组和阿加曲班组,差异有统计学意义(P<0.05);治疗后,除常规组外其他三组血NEUT计数均较治疗前下降(P<0.05),联合组血NEUT计数显著低于常规组、纤溶酶组和阿加曲班组,差异有统计学意义(P<0.05)。4组均无明显不良反应。结论 阿加曲班联合纤溶酶治疗ACI可以明显降低患者血NEUT计数,有效改善患者的神经功能缺损,短期疗效显著,安全性好。
Abstract:Objective To observe the effects of combined application of argatroban and plasmin on the degree of neurological function deficit and neutrophil (NEUT) count in patients with acute cerebral infarction (ACI) and their safety. Methods A total of 221 patients with ACI admitted to The First Affiliated Hospital of Dalian Medical University from October 2018 to January 2022 were selected as the research objects, and they were randomly divided into four groups: control group (n=71), plasmin group (n=42), argatroban group (n=40), and combined group (n=68). All four groups were given conventional treatment, and no other treatment was added to the control group. The plasmin group was added with plasmin injection by intravenous drip, 100 IU on the first day of treatment, and 300 IU on the second day. The argatroban group was pumped intravenously with 10 mg of argatroban injection every 12 hours. The combined group was given argatroban injection and plasmin injection every day (the usage was the same as before). The changes of neurological function deficit and blood NEUT count before and after treatment and the adverse reactions during treatment were observed and recorded. Results After treatment, except for the control group, the National Institutes of Health Stroke Scale (NIHSS) scores of the other three groups were significantly lower than those before treatment (P<0.01). The NIHSS score of the combined group was significantly lower than that of the control group, the plasmin group and the argatroban group, with the statistically significant differences (P<0.05). After treatment, except for the control group, the blood NEUT count of the other three groups decreased compared to before treatment(P<0.05). Blood NEUT count in the combined group was significantly lower than that in the control group, plasmin group, and argatroban group, with the statistically significant differences (P<0.05). There was no obvious adverse reactions in the four groups. Conclusion The combination of argatroban and plasmin in the treatment of ACI can significantly reduce blood NEUT count, effectively improve neurological function deficit, with significant short-term efficacy and good safety.
keywords: Acute cerebral infarction Argatroban Plasmin Neurological function deficit Neutrophil count
文章编号: 中图分类号:R743.3 文献标志码:A
基金项目:
Author Name | Affiliation |
HU Tao, CAO Hong | *Department of Neurology, The Third the People's Hospital of Bengbu, Bengbu, Anhui 233000, China |
引用文本:
胡涛,曹红.阿加曲班联合纤溶酶治疗急性脑梗死的疗效及安全性评估[J].中国临床研究,2024,37(8):1254-1258,1263.
胡涛,曹红.阿加曲班联合纤溶酶治疗急性脑梗死的疗效及安全性评估[J].中国临床研究,2024,37(8):1254-1258,1263.